0001179110-14-003974.txt : 20140228
0001179110-14-003974.hdr.sgml : 20140228
20140228174012
ACCESSION NUMBER: 0001179110-14-003974
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140227
FILED AS OF DATE: 20140228
DATE AS OF CHANGE: 20140228
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 6174983300
MAIL ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Townsend Scott B
CENTRAL INDEX KEY: 0001303192
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10865
FILM NUMBER: 14657087
MAIL ADDRESS:
STREET 1: C/O AMAG PHARMACEUTICALS, INC.
STREET 2: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
edgar.xml
FORM 4 -
X0306
4
2014-02-27
0
0000792977
AMAG PHARMACEUTICALS INC.
AMAG
0001303192
Townsend Scott B
1100 WINTER STREET
WALTHAM
MA
02451
0
1
0
0
SVP, General Counsel
Common Stock
2014-02-27
4
A
0
5000
A
34471
D
Stock Option (Right to Buy)
21.13
2014-02-27
4
A
0
30000
A
2024-02-27
Common Stock
30000
30000
D
Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").
These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (the "Plan") that vests over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal annual installments over the next three years thereafter.
Not applicable.
Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% vesting on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter.
Nancy R. Smith, attorney-in-fact
2014-02-28